BackSoligenix- Warrants (07/12/2021) Overview

Soligenix- Warrants (07/12/2021) EBIT

Track Soligenix- Warrants (07/12/2021)'s EBIT ($-9.6M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$1.38M
↑ 45.64% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$9.60M
↑ 18.27% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Soligenix- Warrants (07/12/2021) (SNGXW) FAQ

The latest EBIT for SNGXW is $-9.6M as of September 2026. That compares with $-12M in the prior-year period — up 18.3% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Soligenix- Warrants (07/12/2021)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, SNGXW's EBIT moved from $-12M to $-9.6M — a 18.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Soligenix- Warrants (07/12/2021)'s operating scale or balance-sheet position.

Against Healthcare companies, SNGXW currently prints $-9.6M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Soligenix- Warrants (07/12/2021)'s growth, margins, and balance sheet.

A EBIT figure of $-9.6M for SNGXW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting SNGXW's EBIT ($-9.6M), review year-over-year change from $-12M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.